Faramarz Ismail-Beigi
Affiliations: | Physiology and Biophysics | Case Western Reserve University, Cleveland Heights, OH, United States |
Area:
General BiophysicsGoogle:
"Faramarz Ismail-Beigi"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Darrell Rubin | grad student | 2004 | Case Western |
| Michael S. Simonson | grad student | 2012 | Case Western |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rahimi L, Malek M, Ismail-Beigi F, et al. (2020) Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature. Advances in Therapy. 37: 3450-3462 |
| Rajpal A, Ismail-Beigi F. (2020) Intermittent Fasting and "Metabolic Switch": Effects on Metabolic Syndrome, Pre-diabetes and Type 2 Diabetes Mellitus. Diabetes, Obesity & Metabolism |
| Rahimi L, Rajpal A, Ismail-Beigi F. (2020) Glucocorticoid-Induced Fatty Liver Disease. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 13: 1133-1145 |
| Yang JF, Gong X, Bakh NA, et al. (2020) Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin. Diabetes |
| Hashemi Madani N, Ismail-Beigi F, Poustchi H, et al. (2020) Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study. Bmc Cardiovascular Disorders. 20: 113 |
| Rege NK, Liu M, Dhayalan B, et al. (2020) "Register-shift" insulin analogs uncover constraints of proteotoxicity in protein evolution. The Journal of Biological Chemistry |
| Razavi-Nematollahi L, Ismail-Beigi F. (2019) Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes. Current Diabetes Reports. 19: 132 |
| Molla GJ, Ismail-Beigi F, Larijani B, et al. (2019) Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran. Canadian Journal of Diabetes |
| Esteghamati A, Ismail-Beigi F, Khaloo P, et al. (2019) Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). Primary Care Diabetes |
| Gharaibeh NE, Rahhal MN, Rahimi L, et al. (2019) SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy. 12: 1001-1012 |